Kinnate Biopharma Sees 20.2% Increase in Trading Interest
April 9, 2023
Trending News ☀️
Kinnate Biopharma ($NASDAQ:KNTE) Inc. has seen a marked increase in trading interest over the past few months, with short interest up 20.2% from last month. Kinnate Biopharma is a publicly traded biotechnology company that develops innovative treatments for diseases of the immune system. The company has recently been making headlines for its breakthrough research in the area of immunotherapy, which has the potential to revolutionize the treatment of cancer and other serious illnesses.
Kinnate Biopharma’s stock has risen sharply as investors see strong potential for growth within the company. With its cutting-edge research and potential for long-term success, Kinnate Biopharma is an exciting opportunity for traders looking to get in on the ground floor of a dynamic new industry.
Market Price
Kinnate Biopharma Inc. saw a significant increase in trading interest this Monday, with the stock opening at $6.3 and closing at $6.8, representing a 9.4% increase from its last closing price of 6.2. This surge in trading activity hints at a market sentiment towards Kinnate Biopharma’s strong prospects in the future. Investors appear keen to capitalise on the potential of this innovative biopharmaceutical company, which is likely to benefit from their broad range of new products. The company’s performance in the coming days and weeks will be closely monitored by investors, as the stock price could potentially continue to rise. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Kinnate Biopharma. More…
| Total Revenues | Net Income | Net Margin |
| 0 | -116.27 | – |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Kinnate Biopharma. More…
| Operations | Investing | Financing |
| -89.03 | -6.83 | 1.16 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Kinnate Biopharma. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 278.83 | 20.36 | 5.04 |
Key Ratios Snapshot
Some of the financial key ratios for Kinnate Biopharma are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 0.0% | – | – |
| FCF Margin | ROE | ROA |
| – | -31.4% | -26.6% |
Analysis
At GoodWhale, we provide investors with an in-depth analysis of KINNATE BIOPHARMA‘s financials. After a thorough assessment of the company’s financials, our Risk Rating indicates that KINNATE BIOPHARMA is a medium risk investment. We have also detected 2 risk warnings in their balance sheet and cashflow statement, which investors should be aware of. To find out more details about the risks, you can register with us. We strive to provide our clients with a comprehensive understanding of the company’s financials so that they can make informed decisions. More…
Peers
The company’s lead product candidate, IPI-549, is an orally-available, small molecule inhibitor of PI3Kγ. The company is also developing IPI-145, an inhibitor of Bruton’s tyrosine kinase (BTK), and IPI-180, an inhibitor of Janus kinases (JAKs). The company’s competitors include Pliant Therapeutics Inc, Epizyme Inc, Gossamer Bio Inc.
– Pliant Therapeutics Inc ($NASDAQ:PLRX)
Pliant Therapeutics, Inc. focuses on the development of therapies for the treatment of fibrotic diseases. The company’s lead product candidate is PLI-300, an orally-administered small molecule that inhibits the production of collagen by blocking the interaction between the alpha2beta1 integrin and collagen. PLI-300 is in Phase II clinical trials for the treatment of idiopathic pulmonary fibrosis and scleroderma. The company was founded in 2015 and is headquartered in San Francisco, California.
– Epizyme Inc ($NASDAQ:GOSS)
Gossamer Bio Inc. is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology. The company’s market cap is $990.28 million and its ROE is -1952.91%. Gossamer Bio’s lead product candidate, GB226, is a Phase 2b-ready monoclonal antibody that is being developed for the treatment of moderate-to-severe atopic dermatitis, a chronic inflammatory skin condition.
Summary
Kinnate Biopharma Inc. recently experienced a 20.2% surge in short interest. This could be interpreted as investors taking a bearish stance on the company’s stock, betting that its stock price will go down.
However, due to the recent market rally, the stock price of Kinnate Biopharma moved up on the same day, indicating that investors may be positioning themselves for a possible long-term uptrend. Although it is too early to make any definitive conclusions, investors should keep a close eye on the stock’s performance and any news coming out of the company. In the meantime, it is advisable to diversify portfolios into other investments and to exercise caution in investing in Kinnate Biopharma stocks.
